Spelling suggestions: "subject:"guillaume, A.""
21 |
Mechanisms of Intravenous Immunoglobulin in the Treatment of Experimental Autoimmune NeuritisLin, Hsin Hsin January 2007 (has links)
PhD / The aims of this study were to test the efficacy of immunoglobulin and its Fab and Fc fragment in the treatment of experimental autoimmune neuritis (EAN) in Lewis rats, to investigate which portion of immunoglobulin is operative in the effect of IVIg, and to clarify the possible mechanisms by which immunoglobulin exerts its action in the treatment of rats EAN. EAN was induced by immunization with whole bovine peripheral nerve myelin. The immunized rats were randomized into groups, assessed clinically, electrophysiologically, and histologically, and intravenously injected with normal saline, albumin, human IVIg preparation, purified Fab or Fc fragments. The treatment efficacy was compared between normal saline and albumin groups, albumin and IVIg groups, albumin and Fab groups, albumin and Fc groups, Fab and Fc groups, Fab and IVIg groups, and Fc and IVIg groups. Methods of myelin isolation, antibody purification, and Western blot techniques were also applied. The results revealed that treatment with Fc fragment and IVIg at the onset of signs of disease effectively prevented further progression of disease, shortened disease duration, and facilitating recovery from illness as shown in clinical, electrophysiological and histological parameters. In the study which the efficacy of albumin and IVIg was compared, 5 out of 17 rats (29%) in the albumin group and 12 out of 17 (71%) in the IVIg group completely recovered from the clinical disease by day 30. The animals receiving IVIg treatment exhibited lower clinical scores, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades. In the study which the efficacy of albumin, Fab fragment, Fc fragment, and IVIg was compared, 0 out of 8 (0%) in the albumin group, 1 out of 8 (13%) in the Fab group, 4 out of 8 (50%) in the Fc group, and 6 out of 9 (67%) rats in the IgG group completely recovered from the clinical disease by day 30. The animals receiving Fc fragment and IVIg treatment exhibited lower clinical scores, less prominent weight loss, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades.
|
22 |
Mechanisms of Intravenous Immunoglobulin in the Treatment of Experimental Autoimmune NeuritisLin, Hsin Hsin January 2007 (has links)
PhD / The aims of this study were to test the efficacy of immunoglobulin and its Fab and Fc fragment in the treatment of experimental autoimmune neuritis (EAN) in Lewis rats, to investigate which portion of immunoglobulin is operative in the effect of IVIg, and to clarify the possible mechanisms by which immunoglobulin exerts its action in the treatment of rats EAN. EAN was induced by immunization with whole bovine peripheral nerve myelin. The immunized rats were randomized into groups, assessed clinically, electrophysiologically, and histologically, and intravenously injected with normal saline, albumin, human IVIg preparation, purified Fab or Fc fragments. The treatment efficacy was compared between normal saline and albumin groups, albumin and IVIg groups, albumin and Fab groups, albumin and Fc groups, Fab and Fc groups, Fab and IVIg groups, and Fc and IVIg groups. Methods of myelin isolation, antibody purification, and Western blot techniques were also applied. The results revealed that treatment with Fc fragment and IVIg at the onset of signs of disease effectively prevented further progression of disease, shortened disease duration, and facilitating recovery from illness as shown in clinical, electrophysiological and histological parameters. In the study which the efficacy of albumin and IVIg was compared, 5 out of 17 rats (29%) in the albumin group and 12 out of 17 (71%) in the IVIg group completely recovered from the clinical disease by day 30. The animals receiving IVIg treatment exhibited lower clinical scores, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades. In the study which the efficacy of albumin, Fab fragment, Fc fragment, and IVIg was compared, 0 out of 8 (0%) in the albumin group, 1 out of 8 (13%) in the Fab group, 4 out of 8 (50%) in the Fc group, and 6 out of 9 (67%) rats in the IgG group completely recovered from the clinical disease by day 30. The animals receiving Fc fragment and IVIg treatment exhibited lower clinical scores, less prominent weight loss, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades.
|
23 |
Der Zusammenhang neurologischer Systemerkrankungen mit Befunden der Energetischen Terminalpunkt-Diagnose (E-T-D) nach Mandel, Kirlian-Fotografie : eine Diagnose-Evaluation am Beispiel des Guillain-Barré-Syndroms und der Multiplen Sklerose /Füss, Robert. January 2007 (has links)
Zugl.: Graz, Interuniversitäres Kolleg für Gesundheit und Entwicklung, Master-Thesis, 2007.
|
24 |
Etiologia da síndrome de Guillain-Barré : uma revisão sistemática de literatura : o que mudou em 10 anos?Wachira, Virginia Kagure 02 February 2018 (has links)
Dissertação (mestrado)—Universidade de Brasília, Faculdade de Medicina, Pós-graduação em Medicina Tropical, 2018. / Submitted by Raquel Viana (raquelviana@bce.unb.br) on 2018-07-03T20:52:33Z
No. of bitstreams: 1
2018_VirginiaKagureWachira.pdf: 1224251 bytes, checksum: a3d6f560ea24acc2a898579963b67cdd (MD5) / Approved for entry into archive by Raquel Viana (raquelviana@bce.unb.br) on 2018-07-09T18:50:35Z (GMT) No. of bitstreams: 1
2018_VirginiaKagureWachira.pdf: 1224251 bytes, checksum: a3d6f560ea24acc2a898579963b67cdd (MD5) / Made available in DSpace on 2018-07-09T18:50:35Z (GMT). No. of bitstreams: 1
2018_VirginiaKagureWachira.pdf: 1224251 bytes, checksum: a3d6f560ea24acc2a898579963b67cdd (MD5)
Previous issue date: 2018-07-03 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). / Introdução: A síndrome de Guillain-Barré é uma polirradiculoneuropatia desmielinizante inflamatória aguda, de natureza autoimune que afeta o sistema nervoso periférico e geralmente é desencadeada por um processo infeccioso agudo. Vários antecedentes etiológicos infecciosos e não infecciosos têm sido associados com a síndrome. A infecção por bactéria Campylobacter jejuni é a causa mais associada com a síndrome, entre outras infecções como citomegalovírus, vírus Epstein-Barr, sarampo, vírus de influenza A, Mycoplasma pneumoniae, enterovirus D68, hepatite A, B, C e o vírus Zika. Objetivo: Descrever os fatores associados ao desenvolvimento da síndrome de Guillain-Barré por meio de revisão da literatura científica e descrever as publicações com enfoque epidemiológico relacionadas à Sindrome de Guillain-Barré antes, durante e depois da epidemia do vírus Zika no Brasil e no mundo, com foco na sua etiologia. Método: Uma revisão sistemática de estudos epidemiológicos a respeito da etiologia da Síndrome de Guillain-Barré publicados no período de 2007 a 2017, antes, durante e depois da epidemia de Zika vírus. As bases de dados utilizados foram EBSCOhost Reseach Databases, Medical Literature Analysis and Retrieval System Online e Literatura Latino-Americana e do Caribe em Ciências da Saúde. A qualidade dos estudos foi avaliada utilizado Newcastle Ottawa Scale. Seguiu os passos da Preferred Reporting Items for Systematic Reviews and Meta-Analyses para o seu relato. Resultados: Um total de 224 artigos foi identificado após a busca nas bases de dados especificadas e após a aplicação dos critérios de inclusão 34 artigos foram selecionados para o estudo, após a leitura completa. Desses artigos, 17 usaram desenho de caso-controle, oito de coorte, cinco Self Controlled Case Series, dois de Self Controlled Risk Interval e dois com desenhos mistos. A qualidade global dos artigos foi considerada alta em relação à maioria dos itens avaliados. Vários agentes etiológicos tiveram resultados indicativos de associação com a síndrome de Guillain-Barré, entre eles: Campylobacter jejuni, vacina da influenza: pandêmica e sazonal, vírus Zika, Mycoplasma pneumoniae, infecção respiratória e gastrointestinal. No período estudado, não houve aumento anual importante no número de estudos que atenderam os critérios de inclusão apesar dos dois eventos de grande impacto na saúde coletiva: a pandemia do vírus da Influenza H1N1 em 2009 e a epidemia do vírus Zika, a partir de 2015 nas Américas. Os agentes encontrados são, na maioria, os mesmos relatados antes do período do estudo. A relação com cirurgias, vírus chikungunya, vírus Zika e a vacina quadrivalente do papilomavírus humano nas meninas (HPV 4 Gardasil) destacam-se como novidades na lista dos diversas possíveis agentes desencadeadores da síndrome de Guillain-Barré relatados no período estudado. Não foram identificados estudos realizados no Brasil nesse período. Conclusões: Os resultados dessa revisão sistemática podem contribuir para o conhecimento dos principais agentes etiológicos envolvidos no desenvolvimento da síndrome de Guillain-Barré e subsidiar a tomada de decisões em saúde, assim como guiar futuras pesquisas, especialmente no momento em que o Brasil vem vivenciando o aumento de casos da síndrome, chamando atenção da comunidade acadêmica, dos serviços de saúde, da comunidade e da imprensa. / Introduction: Guillain-Barré syndrome is an acute inflammatory demyelinating polyradiculoneuropathy, autoimmune in nature that affects the peripheral nervous system and usually triggered by an acute infectious process. Several background infectious and non-infectious etiological factors have been associated with the syndrome. Camplybocter jejuni infection is commonly associated with the syndrome among other infectious causes like citomegalovírus, Epstein-Barr virus, measles, influenza virus, Mycoplasma pneumoniae, enterovirus D68, hepatite A, B, C and Zika virus. Objective: Describe factors associated with the development of Guillain-Barré syndrome by reviewing scientific literature and describing publications with epidemiological approach related to Gullain-Barré Syndrome before, during and after the epidemic of Zika virus in Brazil and in the world with a focus on its etiology. Method: Systematic review of epidemiological studies about the etiology of Guillain-Barré syndrome published between 2007 and 2017, before, during and after Zika virus epidemic. The data bases used were EBSCOhost Reseach Databases, Medical Literature Analysis and Retrieval System Online and Literatura Latino-Americana e do Caribe em Ciências da Saúde. The quality of the studies was evaluated using the Newcastle Ottawa Scale. The study report followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Results: 224 articles were identified after the search in the databases specified and the application of the inclusion criteria, 34 articles were selected for the study after their complete scan. Among the selected articles, 17 had case control design,eight had cohort, five self-controlled case series and two self-controlled risk interval. The quality of the studies was considered good in relation to most of the items evaluated. Many etiological agents had results indicative of association with Guillain-Barré syndrome, among them Campylobacter jejuni, influenza vaccine both pandemic and seasonal vaccines, respiratory infection, gastrointestinal infection among others. The etiological agents found are in most part the same reported prior to the study period. The association with surgeries, chikungunya virus, Zika virus and quadrivalent human papillomavirus vaccine (Gardasil in girls) stand out as new etiological agents in the list of the various possible agents that trigger Guillain-Barré syndrome reported in the study period. There were no Brazilian studies identified during this period. Conclusions: The results of this systematic review can contribute to the knowledge of the main etiological agents involved in the development of Guillain-Barré syndrome and aid in the decision-making process in the health sector, as well as to guide future research especially in Brazil at a time that the increase of cases of the syndrome is attracting the attention of the academic community, health services, the citizens and the press.
|
25 |
Die belewenis van Guillain Barre-pasiente tydens verpleging in intensiewesorgeenhedeJanse van Rensburg, Anna Catharina 05 September 2012 (has links)
M.Cur. / The purpose of this study is to explore and describe the experiences of patients with Guillain-Barré syndrome whilst being nursed in intensive care units, in order to set guidelines for nursing. The researcher made use of the phenomenological approach within the paradigm of qualitative research. The target population consisted of 70 patients of which seven complied with the selection criteria: In-depth interviews, which were taped, were conducted with the patients. Validity and reliability were ensured by using measures as stated by Woods and Catanzaro (1988). Data-analysis was executed by means of Giorgi's method (Omery,1983) and after clearance with an external decoder, it was categorized according to the patients' internal and external environment. The Nursing Theory for the Wholeperson had been used to this purpose. The conclusions of this study indicate that patients with Guillain-Barré syndrome in intensive care units experience deprivation of sleep, pain and fear. Limited communication and loss of autonomy create frustration. Patients become lonely and bored and have a need for constant support from their family and others. Consequent upon the conclusions the researcher developed nine guidelines for the nursing of patients with Guillain-Barré syndrome. These guidelines are in support of the functional approach of the researcher and may be considered an attempt to provide research findings that are applicable to the practice of nursing.
|
26 |
Paranodale und nodale Autoantikörper: Charakterisierung der Anti-Neurofascin-Autoantikörper-assoziierten Neuropathie und Untersuchung des Effektes von Anti-Contactin-1-Autoantikörpern im Zellkulturmodell / Paranodal and nodal autoantibodies: Characterization of the anti-neurofascin autoantibody-associated neuropathy and examination of the effect of anti-contactin-1 autoantibodies in a cell culture modelStengel, Helena Maria January 2022 (has links) (PDF)
Die (Para-)nodopathie ist neben der primär axonalen und der primär demyelinisierenden Polyneuropathie eine neue Krankheitsentität, die sich durch eine Schädigung der Funktion des Ranvierschen Schnürringes auszeichnet. Die Forschung zu (para-)nodalen Autoantikörpern fokussierte sich bislang hauptsächlich auf Neurofascin-155- und Contactin-1-Autoantikörper der Subklasse IgG4.
In dieser Studie wurden die Seren von insgesamt 264 PatientInnen mit CIDP, GBS oder anderen Formen von Polyneuropathien mittels Bindungsassays an murinen Ischiadicuszupfnerven und gegebenenfalls ELISA auf (para-)nodale Autoantikörper gescrennt. Positive Autoantikörperbefunde wurden bei IgG-Autoantikörpern mittels Bindungsassays an transfizierten HEK-293-Zellen und bei IgM-Autoantikörpern mittels Western Blot bestätigt. ELISA Untersuchungen dienten zur näheren Spezifizierung. Weiterhin wurde die zeitabhängige Wirkung von Contactin-1-Autoantikörpern im Zellkulturmodell untersucht.
Die im folgenden dargestellten Ergebnisse zeigen, dass die (Para-)nodopathie nicht auf die bisher am häufigsten beschriebene Erkrankung mit IgG4-Autoantikörpern beschränkt werden sollte.
Bei dem extrem schwer betroffenen IgG-Patient 1 konnte ein Pan-Neurofascin-IgG3-Autoantikörper nachgewiesen werden. Als charakteristische Symptome für diese Autoantikörper konnten in Übereinstimmung mit weiteren Fallberichten Tetraplegie, Beatmungspflichtigkeit sowie eine schwere Hirnnervenbeteiligung bis zur Locked-In-Symptomatik identifiziert werden. Diese Patienten heben sich deutlich von den PatientInnen mit den bisher hauptsächlich beschriebenen Neurofascin-155-IgG4-Autoantikörpern ab, die wie IgG-Patient 2 charakteristischerweise in jungem Alter an einer CIDP mit Tremor ohne Besserung unter IVIG-Therapie leiden.
Es wurden fünf PatientInnen mit Neurofascin-155-IgM-Autoantikörpern identifiziert, die eine akut beginnende Erkrankung mit Tetraparese, Tremor und neuropathischen Schmerzen zeigten. Ob sich dieser Phänotyp als charakteristisch für eine Neurofascin-155-IgM-(Para-)nodopathie bestätigt, sollte in weiteren Studien untersucht werden.
Im murinen Zellkulturmodell an cerebellären Neuronen und Spinalganglienneuronen zeigte sich nach Inkubation mit Contactin-1-IgG-Patientenantikörpern eine zeitabhängige, rasch reversible Verminderung der Contactin-1-Protein-Expression in immunhistochemischen Färbungen sowie Western Blots, die durch eine Internalisierung des Contactin-1-Proteins erklärbar wäre. Der Angriff von Autoantikörpern an Spinalganglienneuronen und cerebellären Neurone sollte in weitere pathophysiologische Überlegungen miteinbezogen werden, da hierdurch typische Symptome der (Para-)nodopathie wie eine sensible Ataxie oder ein cerebellärer Tremor erklärt werden könnten. / (Para-)nodopathy is besides primary axonal and primary demyelinating polyneuropathy a new disease entity characterized by damage to the function of the node of ranvier. Research on (para)nodal autoantibodies has up to now mainly focused on neurofascin-155 and contactin-1 autoantibodies of IgG4 subclass.
In this study sera from 264 patients with CIDP, GBS, or other forms of polyneuropathies were screened for the presence of (para-)nodal autoantibodies by binding assays on murine sciatic nerve and ELISA. Positive autoantibody findings were confirmed by binding assays on transfected HEK-293 cells for IgG autoantibodies and by western blot for IgM autoantibodies. ELISA assays were used for further specification. Furthermore the time-dependent effect of contactin-1 autoantibodies was investigated in a cell culture model.
The results, presented in the following, show that (para-)nodopathy should not be limited to the up to now most commonly described disease with IgG4 autoantibodies.
In the extremely severely affected IgG patient 1 pan-neurofascin IgG3 autoantibodies were detected. In accordance with other case reports tetraplegia, the need for artificial ventilation and severe cranial nerve involvement up to locked-in syndrome could be identified as characteristic symptoms for these autoantibodies. These patients clearly differ from the patients with neurofascin-155 IgG4 autoantibodies, which have been mainly described so far and who, like IgG patient 2, characteristically suffer from CIDP with tremor, have a younger age of onset and do not show improvement under IVIG therapy.
Five patients with neurofascin-155 IgM autoantibodies were identified, who showed acute onset disease with tetraparesis, tremor, and neuropathic pain. Whether this phenotype is confirmed to be characteristic of neurofascin-155 IgM (para-)nodopathy should be investigated in further studies.
In the murine cell culture model of cerebellar granule neurons and dorsal root ganglion neurons, incubation with contactin-1 IgG patient antibodies showed a time-dependent, rapidly reversible decrease in contactin-1 protein expression in immunohistochemical staining as well as western blots, which could be explained by internalization of contactin-1 protein. The effect of autoantibodies on dorsal root ganglion neurons and cerebellar granule neurons should be considered in further pathophysiological considerations, as this could explain typical symptoms of (para-)nodopathy such as sensory ataxia or cerebellar tremor.
|
27 |
Custo-efetividade do uso de imunoglobulina intravenosa e de plasmaferese no tratamento da síndrome de Guillain-Barré no Hospital de Clínicas de Porto Alegre / Cost-effectiveness analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of guillain-barré syndrome in an university-based hospital in the south of brazilBritto, Alexandre Paulo Machado de January 2009 (has links)
Objetivo: Comparar as relações de custo-efetividade de duas terapias, Imunoglubulina Intravenosa (IgIV) e Plasmaferese (PE), no tratamento da Síndrome de Guillain-Barré sob a perspectiva do sistema público (SUS). O objetivo secundário foi avaliar a adesão às recomendações da Comissão de Medicamentos do HCPA Métodos: estudo transversal com análise econômica de pacientes tratados por Síndrome de Guillain-Barré no período de junho de 2003 a junho de 2008 no Hospital de Clínicas de Porto Alegre (HCPA). Foi realizada análise de custo-efetividade do emprego de IgIV e de PE nestes pacientes, pelo método de minimização de custos, considerando-se somente os custos diretos sanitários, fornecidos pelo sistema gerencial da instituição . Foram excluídos os pacientes que usaram outro tipo de tratamento associado ou isolado. Coletaram-se os dados através da revisão dos prontuários. A gravidade da doença na internação foi classificada como: doença leve, quando caminhar foi possível; doença moderada, quando caminhar foi impossível; doença grave, quando os pacientes necessitaram de ventilação assistida. A incapacidade na alta foi estabelecida pela escala de sete pontos de Hughes. A adesão às recomendações da Comissão de Medicamentos do HCPA, objetivo secundário, foi avaliada através da dose e o esquema de prescrição da IgIV. Resultados: Vinte e cinco participantes (2 a 70 anos) foram incluídos no estudo, cinco tratados com PE, empregando-se Albumina Humana como substituto do plasma, e 20 tratados com IgIV. O custo total do tratamento de um paciente com PE foi R$10.603,88 (± 2.978,12) e o de um que recebeu IgIV foi R$ 32.103,00 (± 21.454,24). O custo total da internação foi de R$45.027,14 (± 32.750,45) para os tratados com PE e de R$ 60.844,28 (±48.590,52) para os que receberam IgIV. Em relação ao desfecho clínico principal, melhora na escala de incapacidade de sete pontos, após o tratamento com uma das alternativas escolhida, a mediana dos pacientes que internaram com grau de gravidade 3 e que foram tratados com PE foi igual a dos que receberam IgIV. Em relação à permanência hospitalar, permanência em UTI e dias de Ventilação Mecânica, não houve diferença estatisticamente significativa entre os dois tratamentos. Conclusões: Quando comparados os custos médios das duas opções terapêuticas, uma delas aparece claramente com menor custo. Quando comparados os desfechos, após o emprego de cada opção terapêutica, estes não revelam diferença. Concluímos que, no HCPA, a opção pelo procedimento Plasmaferese é mais custo efetiva do que o emprego da IgIV. / Objectives: To compare the cost-effectiveness of two distinct therapies, Intravenous Immunoglobulin (IVIg) and Plasma Exchange (PE) in the treatment of Guillain-Barré Syndrome, concerning the public health care system. Compliance to the guidelines of the Pharmacy and Therapeutics Committee of the Hospital de Clínicas de Porto Alegre was a secondary objective. Methods: A cross-sectional, economical analysis was conducted, including patients treated for GBS in the period from June, 2003 through June, 2008 in Hospital de Clínicas de Porto Alegre (HCPA). The cost-effectiveness of the use of IVIg and PE in such patients was studied through the cost minimization method, considering direct medical costs only (2008 currency), yield by the management of the institution. Patients receiving treatments other than PE or IVIg were excluded. Data were collected by chart reviews. Severity of disease on admittance was classified as follows: mild disease, when the patient was able to walk; moderate disease, when the patient was unable to walk, and severe disease, when assisted ventilation was required. Disability on discharge was established by the 7-point scale of Hughes. Compliance to the guidelines of the Pharmacy and Therapeutics Committee was evaluated through the dose and prescription scheme of IVIg. Results: Twenty-five participants (2 to 70 years of age) were included in the study, 5 were submitted to treatment with PE, using human albumin as replacement for plasma, and 20 were treated with IVIg. The total treatment cost for PE in a single patient was US$6,058.85 (±1,701.78 SD), and the same expense for IVIg was US$18,344.57 (± 12,259.56 SD) (p = 0.035). Total inpatient cost was US$25,729.79 (± 18,714.54 SD) in the PE group, and US$34,768.16 (±27,766.01 SD) (p=0.530) in the IVIg group. The main clinical outcome was improvement in the 7-point disability grade scale. The median of that measure in patients admitted with a severity grade 3 treated either with PE and IVIg was the same. Secondary outcomes, such as in-hospital stay, ICU stay, and number of days on mechanical ventilation revealed no statistically significant difference between treatments. Conclusions: As the mean expenses of both therapeutic options are compared, one clearly stands-out as less onerous. Clinical outcomes, when compared, reveal no statistical difference after each treatment. We concluded that, in HCPA, plasma exchange is more cost-effective than intravenous immunoglobulin.
|
28 |
Custo-efetividade do uso de imunoglobulina intravenosa e de plasmaferese no tratamento da síndrome de Guillain-Barré no Hospital de Clínicas de Porto Alegre / Cost-effectiveness analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of guillain-barré syndrome in an university-based hospital in the south of brazilBritto, Alexandre Paulo Machado de January 2009 (has links)
Objetivo: Comparar as relações de custo-efetividade de duas terapias, Imunoglubulina Intravenosa (IgIV) e Plasmaferese (PE), no tratamento da Síndrome de Guillain-Barré sob a perspectiva do sistema público (SUS). O objetivo secundário foi avaliar a adesão às recomendações da Comissão de Medicamentos do HCPA Métodos: estudo transversal com análise econômica de pacientes tratados por Síndrome de Guillain-Barré no período de junho de 2003 a junho de 2008 no Hospital de Clínicas de Porto Alegre (HCPA). Foi realizada análise de custo-efetividade do emprego de IgIV e de PE nestes pacientes, pelo método de minimização de custos, considerando-se somente os custos diretos sanitários, fornecidos pelo sistema gerencial da instituição . Foram excluídos os pacientes que usaram outro tipo de tratamento associado ou isolado. Coletaram-se os dados através da revisão dos prontuários. A gravidade da doença na internação foi classificada como: doença leve, quando caminhar foi possível; doença moderada, quando caminhar foi impossível; doença grave, quando os pacientes necessitaram de ventilação assistida. A incapacidade na alta foi estabelecida pela escala de sete pontos de Hughes. A adesão às recomendações da Comissão de Medicamentos do HCPA, objetivo secundário, foi avaliada através da dose e o esquema de prescrição da IgIV. Resultados: Vinte e cinco participantes (2 a 70 anos) foram incluídos no estudo, cinco tratados com PE, empregando-se Albumina Humana como substituto do plasma, e 20 tratados com IgIV. O custo total do tratamento de um paciente com PE foi R$10.603,88 (± 2.978,12) e o de um que recebeu IgIV foi R$ 32.103,00 (± 21.454,24). O custo total da internação foi de R$45.027,14 (± 32.750,45) para os tratados com PE e de R$ 60.844,28 (±48.590,52) para os que receberam IgIV. Em relação ao desfecho clínico principal, melhora na escala de incapacidade de sete pontos, após o tratamento com uma das alternativas escolhida, a mediana dos pacientes que internaram com grau de gravidade 3 e que foram tratados com PE foi igual a dos que receberam IgIV. Em relação à permanência hospitalar, permanência em UTI e dias de Ventilação Mecânica, não houve diferença estatisticamente significativa entre os dois tratamentos. Conclusões: Quando comparados os custos médios das duas opções terapêuticas, uma delas aparece claramente com menor custo. Quando comparados os desfechos, após o emprego de cada opção terapêutica, estes não revelam diferença. Concluímos que, no HCPA, a opção pelo procedimento Plasmaferese é mais custo efetiva do que o emprego da IgIV. / Objectives: To compare the cost-effectiveness of two distinct therapies, Intravenous Immunoglobulin (IVIg) and Plasma Exchange (PE) in the treatment of Guillain-Barré Syndrome, concerning the public health care system. Compliance to the guidelines of the Pharmacy and Therapeutics Committee of the Hospital de Clínicas de Porto Alegre was a secondary objective. Methods: A cross-sectional, economical analysis was conducted, including patients treated for GBS in the period from June, 2003 through June, 2008 in Hospital de Clínicas de Porto Alegre (HCPA). The cost-effectiveness of the use of IVIg and PE in such patients was studied through the cost minimization method, considering direct medical costs only (2008 currency), yield by the management of the institution. Patients receiving treatments other than PE or IVIg were excluded. Data were collected by chart reviews. Severity of disease on admittance was classified as follows: mild disease, when the patient was able to walk; moderate disease, when the patient was unable to walk, and severe disease, when assisted ventilation was required. Disability on discharge was established by the 7-point scale of Hughes. Compliance to the guidelines of the Pharmacy and Therapeutics Committee was evaluated through the dose and prescription scheme of IVIg. Results: Twenty-five participants (2 to 70 years of age) were included in the study, 5 were submitted to treatment with PE, using human albumin as replacement for plasma, and 20 were treated with IVIg. The total treatment cost for PE in a single patient was US$6,058.85 (±1,701.78 SD), and the same expense for IVIg was US$18,344.57 (± 12,259.56 SD) (p = 0.035). Total inpatient cost was US$25,729.79 (± 18,714.54 SD) in the PE group, and US$34,768.16 (±27,766.01 SD) (p=0.530) in the IVIg group. The main clinical outcome was improvement in the 7-point disability grade scale. The median of that measure in patients admitted with a severity grade 3 treated either with PE and IVIg was the same. Secondary outcomes, such as in-hospital stay, ICU stay, and number of days on mechanical ventilation revealed no statistically significant difference between treatments. Conclusions: As the mean expenses of both therapeutic options are compared, one clearly stands-out as less onerous. Clinical outcomes, when compared, reveal no statistical difference after each treatment. We concluded that, in HCPA, plasma exchange is more cost-effective than intravenous immunoglobulin.
|
29 |
Custo-efetividade do uso de imunoglobulina intravenosa e de plasmaferese no tratamento da síndrome de Guillain-Barré no Hospital de Clínicas de Porto Alegre / Cost-effectiveness analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of guillain-barré syndrome in an university-based hospital in the south of brazilBritto, Alexandre Paulo Machado de January 2009 (has links)
Objetivo: Comparar as relações de custo-efetividade de duas terapias, Imunoglubulina Intravenosa (IgIV) e Plasmaferese (PE), no tratamento da Síndrome de Guillain-Barré sob a perspectiva do sistema público (SUS). O objetivo secundário foi avaliar a adesão às recomendações da Comissão de Medicamentos do HCPA Métodos: estudo transversal com análise econômica de pacientes tratados por Síndrome de Guillain-Barré no período de junho de 2003 a junho de 2008 no Hospital de Clínicas de Porto Alegre (HCPA). Foi realizada análise de custo-efetividade do emprego de IgIV e de PE nestes pacientes, pelo método de minimização de custos, considerando-se somente os custos diretos sanitários, fornecidos pelo sistema gerencial da instituição . Foram excluídos os pacientes que usaram outro tipo de tratamento associado ou isolado. Coletaram-se os dados através da revisão dos prontuários. A gravidade da doença na internação foi classificada como: doença leve, quando caminhar foi possível; doença moderada, quando caminhar foi impossível; doença grave, quando os pacientes necessitaram de ventilação assistida. A incapacidade na alta foi estabelecida pela escala de sete pontos de Hughes. A adesão às recomendações da Comissão de Medicamentos do HCPA, objetivo secundário, foi avaliada através da dose e o esquema de prescrição da IgIV. Resultados: Vinte e cinco participantes (2 a 70 anos) foram incluídos no estudo, cinco tratados com PE, empregando-se Albumina Humana como substituto do plasma, e 20 tratados com IgIV. O custo total do tratamento de um paciente com PE foi R$10.603,88 (± 2.978,12) e o de um que recebeu IgIV foi R$ 32.103,00 (± 21.454,24). O custo total da internação foi de R$45.027,14 (± 32.750,45) para os tratados com PE e de R$ 60.844,28 (±48.590,52) para os que receberam IgIV. Em relação ao desfecho clínico principal, melhora na escala de incapacidade de sete pontos, após o tratamento com uma das alternativas escolhida, a mediana dos pacientes que internaram com grau de gravidade 3 e que foram tratados com PE foi igual a dos que receberam IgIV. Em relação à permanência hospitalar, permanência em UTI e dias de Ventilação Mecânica, não houve diferença estatisticamente significativa entre os dois tratamentos. Conclusões: Quando comparados os custos médios das duas opções terapêuticas, uma delas aparece claramente com menor custo. Quando comparados os desfechos, após o emprego de cada opção terapêutica, estes não revelam diferença. Concluímos que, no HCPA, a opção pelo procedimento Plasmaferese é mais custo efetiva do que o emprego da IgIV. / Objectives: To compare the cost-effectiveness of two distinct therapies, Intravenous Immunoglobulin (IVIg) and Plasma Exchange (PE) in the treatment of Guillain-Barré Syndrome, concerning the public health care system. Compliance to the guidelines of the Pharmacy and Therapeutics Committee of the Hospital de Clínicas de Porto Alegre was a secondary objective. Methods: A cross-sectional, economical analysis was conducted, including patients treated for GBS in the period from June, 2003 through June, 2008 in Hospital de Clínicas de Porto Alegre (HCPA). The cost-effectiveness of the use of IVIg and PE in such patients was studied through the cost minimization method, considering direct medical costs only (2008 currency), yield by the management of the institution. Patients receiving treatments other than PE or IVIg were excluded. Data were collected by chart reviews. Severity of disease on admittance was classified as follows: mild disease, when the patient was able to walk; moderate disease, when the patient was unable to walk, and severe disease, when assisted ventilation was required. Disability on discharge was established by the 7-point scale of Hughes. Compliance to the guidelines of the Pharmacy and Therapeutics Committee was evaluated through the dose and prescription scheme of IVIg. Results: Twenty-five participants (2 to 70 years of age) were included in the study, 5 were submitted to treatment with PE, using human albumin as replacement for plasma, and 20 were treated with IVIg. The total treatment cost for PE in a single patient was US$6,058.85 (±1,701.78 SD), and the same expense for IVIg was US$18,344.57 (± 12,259.56 SD) (p = 0.035). Total inpatient cost was US$25,729.79 (± 18,714.54 SD) in the PE group, and US$34,768.16 (±27,766.01 SD) (p=0.530) in the IVIg group. The main clinical outcome was improvement in the 7-point disability grade scale. The median of that measure in patients admitted with a severity grade 3 treated either with PE and IVIg was the same. Secondary outcomes, such as in-hospital stay, ICU stay, and number of days on mechanical ventilation revealed no statistically significant difference between treatments. Conclusions: As the mean expenses of both therapeutic options are compared, one clearly stands-out as less onerous. Clinical outcomes, when compared, reveal no statistical difference after each treatment. We concluded that, in HCPA, plasma exchange is more cost-effective than intravenous immunoglobulin.
|
30 |
Efeito da crotapotina na evolução clinica da neurite experimental autoimune (EAN) / Effect of crotapotin on clinical evolution of experimental autoimmune neuritisCastro, Fabiano Roberto de 21 March 2006 (has links)
Orientador: Leonilda Maria Barbosa dos Santos / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-07T03:41:32Z (GMT). No. of bitstreams: 1
Castro_FabianoRobertode_M.pdf: 943470 bytes, checksum: 271c21deb3b25015f9737d33adf49814 (MD5)
Previous issue date: 2006 / Resumo: A Síndrome de Guillain-Barré (SGB) é uma doença desmielinizante do sistema nervoso periférico (SNP). Baseado principalmente nas similaridades clínicas e histopatológicas a Neurite Experimental Auto-imune (EAN) tem sido extensivamente usada como modelo de estudo da SGB. A EAN é uma doença auto-imune, que pode ser experimentalmente induzida em ratos geneticamente suscetíveis através da imunização com os componentes da mielina de nervos periféricos tais como os peptídeos P0 e P2 , ou ainda por transferência adotiva de lifócitos T CD4+ do tipo Th1. Diferentes tentativas de tratamentos para a SGB têm sido estudadas, dentre elas pode-se citar a plasmaferese, o uso de anticorpos monoclonais, administração de corticóides e a imunossupressão global através da administração de intérferon ß. A utilização de venenos totais de serpentes, ou frações deles, já demonstrou bons resultados na tentativa de tratamento de alguns modelos de doenças auto-imunes como a diabetes auto-imune insulino dependente, lúpus e encefalomielite experimental auto-imune (EAE). No presente trabalho foi estudado o efeito de uma fração do veneno da cascavel sul americana Crotalus durissus terrificus (Cdt), a crotapotina, no modelo de EAN. São apresentadas evidências de que tanto a administração intraperitoneal (IP) como a oral de crotapotina reduz significativamente a gravidade da EAN induzida em ratos Lewis, associada a um significativo declínio na resposta proliferativa das células T neuritogênicas, assim como diminuição de infiltrados de células mononucleares no nervo ciático dos os animais / Abstract: Biomedical research in which venom components are being investigated for their potential as novel therapeutic agents has emerged as an interesting option. Crotapotin which is a fraction of the venom of the rattlesnake Crotalus durissus terrificus, has been described as an antinflammatory that acts on the innate arm of the immune response. Here we have demonstrated that intraperitoneal (IP), as well as oral administration of crotapotin significantly reduces the severity of experimental autoimmune neuritis (EAN), an experimental model for Guillain-Barré Syndrome. The reduction of the severity of the disease is associated with a reduction in the mononuclear cells infiltrating in the sciatic nerve and a significant decrease in the lymphocyte proliferative response to neuritogenic peptide / Mestrado / Ciencias Basicas / Mestre em Clinica Medica
|
Page generated in 0.0285 seconds